In most operating and recovery rooms, shivering is controlled by the use of humidifiers, warming blankets, and inhalation of humidified heated oxygen. However, pharmacological control is an effective alternate treatment modality. This randomized, double-blind trial, conducted in 30 ASA Grade I or 2 patients, was designed to explore the efficacy of tramadol and pethidine in the treatment of post-anaesthetic shivering.
Shivering is a post-anaesthetic complication influenced by the type of anaesthetic used. Halothane, enflurane and isoflurane are associated with a high incidence of shivering (over 60%) 1 . Opioid and nitrous oxide-based anaesthesia is associated with an incidence only half that of halothane-based maintenance of anaesthesia. Mild shivering increases oxygen consumption to a level similar to that produced by light exercise, whereas in severe shivering, patients may show a 500% increase in oxygen consumption 2 . Such a large oxygen demand can only be satisfied by considerable increase in minute volume ventilation and cardiac output. As some patients may not be able to increase these cardiorespiratory parameters adequately and because all patients feel uncomfortable, attempts have been made to prevent its occurrence. Equipment to maintain normothermia is effective in preventing shivering, but may be expensive and is not practical in all settings 3 .
Pharmacological control is effective and can be used when clinically indicated. Many drugs have been used to treat shivering, including pethidine (meperidine), doxapram, tramadol, ketanserin, clonidine, propofol, physostigmine, nefopam, alfentanil and sufentanil [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Success rates range from 30 to 95%, with pethidine usually proving the most efficacious 2 . Pethidine, however, confers many disadvantages 3 , for example postoperative nausea and vomiting. Tramadol, a novel analgesic with several antinociceptive effects, inhibits the reuptake of noradrenaline and 5-hydroxytryptamine-3 (5-HT3) 15 . Both these mechanisms are also involved in temperature regulation. Recent studies have investigated the efficacy of tramadol in the control of shivering 17, 18 , but to date tramadol has not been compared with other drugs.
This randomized, double-blind study was designed to compare the efficacy of tramadol and pethidine in the treatment of post-anaesthetic shivering following general anaesthesia.
MATERIALS AND METHODS
This prospective, double-blind, randomized study was conducted at our Institution from March to September 1999. Institutional Ethics Committee clearance and informed consent from all patients were obtained prior to operation. It was explained that if shivering were to occur postoperatively, one of the two study drugs would be given to control it. All patients during the study period were recruited, but only those who shivered were randomized. The first thirty consecutive patients who developed shivering, either immediately or within 10 minutes of transfer to the recovery room following a general anaesthetic, were included in this study.
The exclusion criteria were haemodynamic instability; patients of American Society of Anesthesiologists (ASA) Grade 3 or 4 or age above 65 years; those who had received pethidine or tramadol intraoperatively; and those needing ventilatory support or with a recovery room sedation score of 3 (where 0= alert; 1=drowsy; 2=sleeping but rousable and 3= unrousable).
Following surgery patients were moved to the postanaesthesia recovery unit on an adjustable bed covered with a cotton blanket and were surrounded by electric convective warm air blowers. The temperature of the recovery room was noted for each case. Monitoring of pulse rate (PR), non-invasive blood pressure (NIBP), electrocardiogram changes (ECG), oxygen saturation (SpO 2 ) and nasopharyngeal temperature were carried out using the Cardiocap Monitor (Cardiocap-II combined with Capnomac Ultima model ULT-I, Datex). Patients who shivered were randomized and the severity of shivering graded on a scale of 0 to 3 (0=no shivering; 1=mild fasciculation of the face and neck with no ECG disturbance; 2=visible tremor involving more than one muscle group and disturbance of ECG on cardioscope; 3=muscular activity involving the entire body). Monitoring was continued after study drug administration at 10-minute intervals for 60 minutes.
Injections of tramadol 10 mg/ml and pethidine 5 mg/ml were prepared in 10 ml syringes using a computer-generated random number list, and the syringes labelled serially. Patients received 0.1 ml/kg of the assigned drug intravenously over 90 seconds. Neither staff monitoring the patient nor the patients were aware of group allocation. The code was broken at the end of the study period of sixty minutes.
Drug efficacy was assessed on the basis of a sustained decrease in the grade of shivering. Side-effects (e.g., changes in haemodynamic status, 0 to 3 sedation score or other untoward effects) were assessed. The study was considered completed in 60 minutes, but patients were observed for another 30 minutes to verify that shivering did not recur.
The incidence of shivering between the groups at each point of time was calculated using the Wilcoxon Rank Sum test and within each group using Freedman two-way analysis of variance. The P value of <0.05 was considered statistically significant.
RESULTS
There were no statistical inter-group differences in age, weight, PR, NIBP, respiratory rate (RR), temperature of the recovery room or grade of shivering at entry to the study (Table 1 ). There was a male preponderance in both groups.
The number of patients who stopped shivering within 10 minutes of receiving tramadol was significantly higher than after pethidine (12/15 vs 4/15, P<0.05). This response was sustained until 30 minutes after drug injection ( Figure 1 ).
Shivering had stopped in all but one patient in the pethidine group and in all patients in the tramadol group at the end of one hour. Eighty per cent of patients had stopped shivering by 10 minutes after tramadol and by 40 minutes after pethidine. None of the patients in the tramadol group recommenced shivering, whereas five patients developed shivering within 10 minutes of an initial response in the pethidine group. Patients receiving tramadol had a significantly lower severity of shivering from 10 to 30 minutes after drug injection compared with patients receiving pethidine (P<0.05, Table 2 ). Sedation score after 60 minutes was similar for both groups ( was significant after 30 minutes in the tramadol group and after 60 minutes in the pethidine group (Figure 2 ).
There were no significant differences in NIBP, PR and RR after drug administration at any time interval (Table 3 ). Nausea and vomiting occurred in one patient in the pethidine group and none in the tramadol group.
DISCUSSION
Although the aetiology of postoperative shivering is inadequately understood, various risk factors have been suggested. These include hypothermia, stress, uncontrolled pain, uninhibited spinal reflexes and decreased sympathetic activity. Many drugs have been used to treat shivering, including opioids, doxapram, tramadol, ketanserin, clonidine, propofol, physostigmine and nefopam, with opioids being the most extensively evaluated 2 . Amongst the opioids, pethidine has been found to be most efficacious 16 . Evidence suggests that kappa-opioid receptors play an important role in the modulation of postoperative shivering 5, 6, 7 . This explains the greater efficacy of pethidine compared with equi-analgesic doses of mu-receptor opioid agonists such as morphine, fentanyl, alfentanil and sufentanil 8, 9, 10 . The analgesic potential of tramadol is believed to be mediated weakly through its effect on the mu-opioid receptor, for which it has a low affinity. Of greater importance may be its effect on 5-HT3 and noradrenergic receptors, with activation of descending inhibitory pathways producing antinociception. The R (+) enantiomer of tramadol inhibits 5-HT3 uptake and enhances its release, while the L (-) enantiomer inhibits nonadrenaline uptake 17, 18 . Electrophysiologic, neurophysiologic and neuropharmacologic experiments in animals have established the role of noradrenaline and 5-HT3 in the control of body temperature 19 . Activation of the nucleus raphe magnus, where 5-HT3 acts as a neurotransmitter, has an inhibitory effect on shivering. It is thus possible that the antishivering effect of tramadol is mediated by its effect on these receptors. We postulated that it was likely to have better clinical utility compared with pethidine for the management of postoperative shivering.
The results of this study support other studies indicating that the analgesic drug tramadol is effective in the treatment of postanaesthetic shivering, and show that its efficacy is significantly better than pethidine during the first 30 minutes after administration. The percentage of patients who stopped shivering after tramadol 1 mg/kg (80%) was lower than in an earlier study in which its efficacy was documented as 100% after doses of 1 to 2 mg/kg 17 . The response rate (5 to 30 minutes after treatment) with pethidine has been documented as 83 to 93% 20 . In our study, the response rate to pethidine was only 80% after 40 minutes and more than 50% of patients receiving pethidine suffered a recurrence of shivering within 10 minutes of the initial response. The mean core temperature in the study by Dewitte 17 , in which a 100% response to tramadol was observed, was higher (in the range of 35.6±0.5°C) compared with that of patients in our study (33.57 to 34.26°C). One of the factors influencing the lower response rates with both tramadol and pethidine in our study may have been the lower core temperature of our patients, all Values are median (interquartile range) except temperature, which is mean (±SD); n=15 (for both drugs). *P<0.05. Temperature is significantly raised at the end of 60 min in the pethidine group (P<0.05) whereas in the tramadol group temperature rise from the base line temperature is significant at the end of 30, 40, 50 and 60 minutes (P<0.05). *P<0.05 of whom had undergone eight to ten hours of extensive head and neck surgery for malignancy. Although no correlation could be demonstrated between core temperature and grade of shivering, we believe that core temperature may be an important factor influencing the rate of increase of temperature rise during shivering. Further research is required to understand the relation between core temperature and rate of temperature rise.
None of the patients in this study had adverse effects due to either pethidine or tramadol, however pethidine is considered to be associated with more postoperative nausea, vomiting, sedation and respiratory depression.
In conclusion, tramadol in a dose of 1 mg/kg is a more effective drug for the treatment of postoperative shivering than pethidine 0.5 mg/kg, and it is not associated with haemodynamic disturbances, excessive sedation or other side-effects. It should be considered in any patient who shivers postoperatively.
